

August 25, 2020

The Manager, Listing Department The National Stock Exchange of India Ltd. Exchange Plaza, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051

**NSE Symbol: PANACEABIO** 

BSE Limited Corporate Relationship Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai - 400 001

BSE Scrip Code: 531349

Reg.: Board Meeting on September 03, 2020 for approving the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2020

Dear Sir,

Pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI LODR Regulations"), this is to inform you that a meeting of the Board of Directors of the Company is scheduled to be held on Thursday, September 03, 2020 at New Delhi, inter-alia, to consider and approve the Standalone and Consolidated Unaudited Financial Results (Provisional) for the quarter ended June 30, 2020.

Further, pursuant to Regulations 46(2) & 47(1) of the SEBI LODR Regulations, notice of the said meeting is also being sent for publication in newspapers and uploaded on the website of the Company.

Further, with reference to our earlier announcement dated June 30, 2020 intimating the Closure of Trading Window pursuant to the Company's Code of Conduct for Prevention of Insider Trading framed in accordance with SEBI (Prohibition of Insider Trading) Regulations, 2015, as amended from time to time, we would like to inform that the trading window of the Company shall remain closed for all the Designated Persons of the Company and Material Subsidiaries of the Company till September 05, 2020.

This is for your kind information and record please.

Thanking you, Sincerely yours, for Panacea Biotec Ltd.

Devender Gupta

Chief Financial Officer and Head IT